HCW Biologics Poster Presentation at AACR Annual Meeting 2023
13 Abril 2023 - 8:15AM
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ:
HCWB), a clinical-stage biopharmaceutical company focused on
discovering and developing novel immunotherapies to lengthen
healthspan by disrupting the link between inflammation and
age-related diseases, today announced that data for the mechanism
underlying HCW9218 against solid tumors will be presented at the
2023 Annual Meeting of the American Association for Cancer Research
to be held in Orlando, Florida from April 14 – April 19, 2023.
HCW9218 is an injectable, bifunctional fusion
protein complex designed to simultaneously stimulate effector T
cell and natural killer cell responses and inhibit the activity
of TGF-β and its immunosuppressive effect. There are
currently two ongoing clinical trials to evaluate HCW9218 in solid
tumors. A Company-sponsored Phase 1b/2 clinical trial in patients
with chemo-refractory/chemo-resistant pancreatic cancer currently
has four clinical sites enrolling patients. The Masonic Cancer
Center, University of Minnesota is sponsoring a Phase 1 study to
evaluate HCW9218 in various solid tumors. The Company selected
chemo-refractory/chemo-resistant solid tumors for its first
clinical indications because solid tumor cancers are characterized
by a dense fibrotic stroma or desmoplasia that allows a tumor to
shield itself from standard-of-care treatment, such as chemotherapy
and immune-checkpoint inhibitors. The immunosuppressive growth
factor, TGF-β, plays a major role in formation of desmoplasia and
promoting tumor growth and metastasis.
Details of the presentation are as follows:
Session Category: |
Clinical Research Excluding Trials |
Session Title: |
Immunomodulatory Agents and Interventions |
Abstract Title: |
Bifunctional immunotherapeutic
HCW9218 facilitates recruitment of immune cells from tumor draining
lymph nodes to promote antitumor activity and enhance checkpoint
blockade efficacy in solid tumors |
Presenter(s): |
Pallavi Chaturvedi, Ph.D. and
Varghese George, Ph.D. |
Session Date and Time: |
Tuesday April 18, 2023 9:00 AM - 12:30 PM, Eastern |
Location: |
Poster Section 40 |
Poster Board Number: |
27 |
Published Abstract
Number: |
4441 |
The poster presentation will be made available
on the Company’s website in the Investors section under Events
& Presentations, following the conference.
For conference information, visit: AACR Annual
Meeting 2023 | Meetings | AACR
About HCW Biologics:
HCW Biologics is a clinical-stage
biopharmaceutical company focused on discovering and developing
novel immunotherapies to lengthen healthspan by disrupting the link
between chronic, low-grade inflammation, and age-related diseases,
such as cancer, cardiovascular diseases, diabetes,
neurodegenerative diseases, autoimmune diseases, as well as other
conditions such as long-haul COVID-19. The Company has combined a
deep understanding of disease-related immunology with its expertise
in advanced protein engineering to develop the TOBI™ (Tissue
factOr-Based fusIon) discovery platform. The Company uses its
TOBI™ discovery platform to generate designer, novel
multi-functional fusion molecules with immunotherapeutic
properties. The invention of HCW Biologics’ two lead molecules,
HCW9218 and HCW9302, was made via the TOBI™ discovery platform. The
Masonic Cancer Center, University of Minnesota, has initiated a
Phase 1 clinical trial to evaluate HCW9218 in
chemo-refractory/chemo-resistant solid tumors that have progressed
after prior chemotherapies (Clinicaltrials.gov: NCT05322408). The
Company is also enrolling patients in a Company-sponsored Phase
1b/2 clinical trial to evaluate HCW9218 in
chemo-refractory/chemo-resistant advanced pancreatic cancer
(Clinicaltrials.gov: NCT05304936). The Company’s lead molecule for
its regulatory T cell expansion program, HCW9302, is currently
undergoing IND-enabling studies for an autoimmune indication.
Forward Looking
Statements:Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. These statements are made under the “safe
harbor” provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words and
include, without limitation, statements regarding the ability of
HCW9218 to stimulate effector T cell and natural killer cell
responses and inhibit the activity of TGF-β; the ability of
HCW9218 to treat cancer. Forward-looking statements are based on
the Company’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
in the annual report on Form 10-K filed with the United States
Securities and Exchange Commission (the “SEC”) on March 28, 2023
and in other filings filed from time to time with the SEC.
Forward-looking statements contained in this press release are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Company Contact:Rebecca
ByamCFOHCW Biologics Inc.rebeccabyam@hcwbiologics.com
HCW Biologics (NASDAQ:HCWB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
HCW Biologics (NASDAQ:HCWB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024